



Lions Cancer Institute Inc

Saving Lives in our Communities through Research and Skin Cancer Screening Since 1990



MOBILE SKIN CANCER SCREENING FACILITY



Annual Report

2021-2022

OUR PATRONS



Emeritus Professor George Yeoh
BSc, PhD
Laboratory Head,
Liver Development & Cancer,
Harry Perkins Institute of Medical Research

Dear Friends of the Institute

This past year, the focus has been on the COVID pandemic. Undeniably, its impact on the health of the community as well as medical researchers has been enormous. Directly, everyone has been affected; however, a less obvious, but no less important consequence of the pandemic is the concentration of effort dealing with it resulting in reduced resources to cancer patients. In addition, research laboratories have faced a myriad of issues that have curtailed their work. Delays in obtaining reagents, equipment and a reduced or total lack of access to laboratories to name a few.

It is in the context of these challenges that the efforts of the Institute this past year should be considered. As far as cancer is concerned, it remains true that “prevention is better than cure”, “early detection improves prognosis” and “knowledge is power”; all of which provide better outcomes for patients.

It is pleasing to learn that Institute’s screening program maintains its level of activity and continues to identify life threatening lesions that are referred. It is most certainly contributing towards the need to address the poorer outcome of cancer patients in our rural community. All concerned with this program deserve recognition and our thanks.

Improved outcomes for patients with all types of cancer has come about because of increased knowledge. Identifying causal factors, understanding the progressive stages that produce the cancer and discovering effective anti-cancer agents and incorporating these into treatment protocols are the fruits of research. Research is primarily an activity that relies on engaging dedicated, hard-working and talented people. It is extremely pleasing to record in this report that the Institute has increased its commitment to supporting researchers by providing an additional Lions-Lotus PhD scholarship to Ms Anjali Ghimire to one awarded to Mr Nathan Main, both working at Curtin University.

It also continues to co-fund student support under the Karen & Joshua Chinnery Scholarship nominated by and together with the Cancer Council of WA. The latest students, Hannah Newnes and Samantha Barnes undertake their studies at the Telethon Kids Institute. There cannot be better ways to invest in research than to support the career advancement of smart West Australians.

In closing, I commend the Board of the Institute for its strategy to improve outcomes for cancer patients and its courage to tackle cancers that are difficult to treat.

To all friends and supporters of the Institute, continue your good work. You are a team that improves the lives of many.

Thank you.
George Yeoh

A handwritten signature in black ink that reads "George Yeoh". The signature is written in a cursive, flowing style.

BOARD OF DIRECTORS

CONTENT

ELECTED MEMBERS

Lion Phil Chinnery	Chairman
PDG Michael Wainwright	Vice Chairman
PDG Pamela Baird	Director
PDG Garry Irvine	Director Business Development
Lion Pip Dargaville	Director
Lion Hans Hoette	Director
Lion Christine Walker	Director
Lion John Osborne	Director Screening Event Coordinator
Lion Graham Bateman	Director
Lions David Turnell	Director

APPOINTED MEMBERS

Lion Robert Garratt	Treasurer
Mr William Crosthwaite	Secretary
Mr Rob Fitzpatrick, FRCS, FRACS	Chair Medical & Scientific Advisory Committee

EX OFFICIO MEMBERS

DG Michael Wolf	District 201W1
DG Stephen Berry	District 201W2
1 st VDG Darren Blackburn	District 201W1
1 st VDG. Ted Watts	District 201W2
2 nd VDG Tim Moore	District 201W1

CO-OPTED, NON-VOTING, MEMBERS

PDG Neil Saunders	Finance & Administration Advisor
Lion David Baird	Assistant Treasurer

2022 Board of Directors	3
Chairperson	4
Our Incomes	5
Business Development	6
Organisational Chart	7
Medical Director	8
Media Release	9
Screening Events Manager	10-11
PhD Student – Samantha Barnes	13
PhD Student – Hannah Newnes	14
PhD Student – Anjali Ghimire	15
PhD Student – Nathan Main	16
Treasurer	18
Financial Report	19-24
Club Donations	26
Life Fellows of LCI	27



The Lions Cancer Institute (WA) Inc. is a “Not For Profit” medical research institution. The Institute holds an Endorsement from the Australian Tax Office as an income tax exempt charitable entity (ITEC) and is a deductible gift recipient (DGR).

The Institute holds a licence issued under the provisions of the Charitable Collections Act.

Auditor/Accountant is Auditax Accountants
Independent Auditor, Daniel Papaphotis
Registered Company Auditor, # - 410503
Francis A Jones Pty. Ltd.
Fremantle WA 6160.

Institute website: www.lionscancerinstitute.org.au

CHAIRPERSON'S REPORT



LION PHIL
CHINNERY

It is my pleasure to provide this report on the status and progress of the Lions Cancer Institute Inc. over the preceding 12 months July 2021 to June 2022.

SKIN CANCER SCREENING

The Lions Cancer Institute Inc. commenced its screening program in 1990 and has conducted free skin cancer screenings continuously, now operating as the Lions Cancer Institute (WA) Inc. It has screened in the order of 87,000 people in that time, from all over Western Australia. Covid 19 did not cause any delays this year, and due to the excellent roster planning work by Screening Events Manager Lion John Osborne, 38 locations were visited in this report period.

Under the leadership of Medical Director Robert Fitzpatrick, it is very pleasing that we have an increased number of screeners available this year. Many of these volunteers have been with us for numerous screening events which enabled them to increase their skills and knowledge substantially.

EQUIPMENT REPLACEMENT

The big news for this report is that we have just received notification of being granted USD 73,529 (approx. AU\$107,021) from LCIF to help fund our new mobile screening Unit.

Two years ago, an invitation was sent to all Clubs in WA to pledge a yearly donation for three years to provide base funding to replace our aging Unit. I thank those Clubs that have been able to pledge for their generous support, which is projected to total a little over \$185,000. This combined with nearly \$100,000 in substantial donations from the corporate sector and approximately \$157,000 other business and private donations meant we can proceed with final design details and place an order to have the new Unit built, with delivery expected during the second half of 2023.

PROMOTION

The Institute continues to provide advice and support to the Victorian and South Australian/Northern Territory Skin Screening Projects. Together with the help of Ambassador Deborah Hutton we continue to encourage the Q, N and T Districts to get the Free Skin Screening project going in their States. The efforts over the years by Director Garry Irvine to encourage our associates in New Zealand is coming to fruition with the launch of the Project due early 2023.

RESEARCH

The Institute is continuing to support through the Karen & Joshua Chinnery Scholarship, two PhD students attending Curtin University. Hannah Newnes is part funded by the scholarship for a further year and new student Samantha Barnes was selected for top up funding support for two years. Medical Director Rob Fitzpatrick will maintain contact with them during their time under the scholarships.

The Lions-Lotus PhD Scholarship, fully funded by The Lions Cancer Institute is based in the Curtin Health Innovation Research Institute (CHIRI), at Curtin University. Nathan Main continues his studies in the prevention and treatment of liver cancer. A second Student, Anjali Ghimire was awarded a position with CHIRI early this year. Her research has the aim of developing a new approach to detect early signs of future liver cancer development. Anjali will attend and speak at the AGM in October.

INSTITUTE MANAGEMENT

Throughout this annual report you will also read reports from our Treasurer Lion Robert Garratt, PR & Business Development Director PDG Garry Irvine, Screening Events Manager Lion John Osborne, Medical Director Rob Fitzpatrick FRCS, FRACS -Plastic Surgeon (Retired), Finance and Administration Advisor PDG Neil Saunders and our current PhD students.

The Institute is well served by a Board consisting of Lions Club members and willing Volunteers, both in the administration of the Institute and on our skin cancer screening events throughout the State of Western Australia. To you all I offer my sincere thanks for your dedicated involvement.

■ Lion Phil Chinnery—Chairman



OUR INCOMES

Current funding is primarily from:

- a. **Telemarketing:** Telemarketer is contracted to source donations from parties excluding Lions Clubs and private individuals. In particular special attention is given to the Children's Big Day Out event. There are substantial fees for the collection of these funds.
- b. **Donations from Lions Clubs:** these are usually annual donations and vary in size from club to club depending on available funds and knowledge of the Institute.
- c. **Bequests.**
- d. **Private donations.**
- e. **Corporate donations.**
- f. **Grain growers.**

Competitors for funds include:

- a. Other Lion's projects.
- b. Other telemarketing operations.
- c. Other charities.
- d. Other research organisations.



▲ BIG DAY OUT FOR SPECIAL NEEDS CHILDREN

Special
Children's
Big Day Out

BUSINESS DEVELOPMENT



PDG GARRY IRVINE

It is a privilege to have been part of the volunteers who ensure the work of the Institute and the valuable health service provided to all WA communities. The 30 years of input from both past and present persons has seen free full body skin cancer screenings expand across Australia and the Lions Districts of NSW and QLD are currently in the process of instituting similar services for their communities.

As our State progresses towards 2024 our International Association of Lions Clubs has agreed that a new Single District be formed here in WA and so our two previous Districts will become one – a new opportunity for informing the communities in WA about our Lions Clubs and about - What we do, Who we are and What we need.

MARKETING

Within this Budget were opportunities for us to inform the Communities around our urgent need to replace our aging mobile screening vehicle and that was achieved in articles provided to Farmers Weekly and Have a Go newspapers. As at this Report we are hastening towards placing an order and expect we may have our new purpose-built Unit in mid to late 2023.

Country Shires have also joined with CRC's and our Local Lions Clubs to promote our free full body skin cancer screenings all supported by our Professional GPs, Dermatologists, Dermoscopists and a retired Plastic Surgeon.

SKIN SCREENING SERVICES

Within our Screening Director's Report will be a list of the many areas of the State we visit to provide what even the medical persons refer to as a valuable 'health service'.

However, trying to raise over \$700K to replace our aging Unit is far from an easy task with letters of requests for funding from within our Lions Clubs having been made plus to a large number of Corporates being submitted. We are delighted to advise that a large amount of the monies raised to date were received from those quarters.

The major disappointment to us was how poorly our service was treated by the Health Dept. WA with even the Federal Minister being approached and his Dept. replying negatively. By comparison in Victoria the State Govt. were deeply involved with supporting their new Lion's skin check service and the State Governor extended invitations to innumerable

community members to attend the official opening of that new skin cancer screening service.

Additionally, we had approached Lotterywest whom we thought would be an obvious chance for us to be helped, yet even with the support for our application from a couple of WA State Ministers, they declined to help us, it must be said if they can't help then the question has to be – why? – are we not a valued and valuable community service?

EASTERN STATES

As this Annual Report is being prepared it is very exciting to note that both NSW and QLD Lions Clubs' Districts have established Lions Committee to investigate the possibility of creating skin screening services within those two States, in addition with great support from Victoria, Tasmania are progressing similarly. We acknowledge the interest and support of Ambassador for Lions Skin Screening projects in Australia, television personality Deborah Hutton.

It will be a proud moment for those of us that have volunteered for over 30 years to finally see the Lions Clubs of this nation become the driving force to establish free full body skin cancer screenings for all who choose to visit our mobile services – one where we come to you !!!!

NEW ZEALAND

As at this Report a small contingent of Australian Lions have been working with Lions in NZ to provide similar services for NZers and no Lion has provided more effort in that regards than PDG Paul O'Connor, MBE who continues to drive forward this Project, Paul, we salute you and will always be with you to see the journey through.

RESEARCH

Our Institute has funded cancer research since inception 32 years ago, it continues today with our more recent association with Curtin University and the establishment of the Lions-Lotus Scholarship where we have quality PhD Students performing important research funded by the Institute. Prior to that scholarship we have enjoyed the all-important support from the long-established Karen & Joshua Chinnery Scholarship funded significantly by the Armadale-Kelmescott Lions Club, the Club of which our current Chairman is a member and the prime mover for its existence.

OUR FUTURE


As we progress to continue to offer our free 'health service' we will endeavour to seek lawful avenues on gathering information voluntarily from our Patients so we can record that what was referred for further attention by those Patient's GP is in fact serious or not. We know we save lives, but we are held back in trying to prove that.

I acknowledge the dedication of my fellow Board Members and our Chairman Lion Phil, 2023 will prove to be another success story.

■ Garry K Irvine PDG



ORGANISATIONAL CHART



MEDICAL DIRECTOR'S REPORT



ROBERT FITZPATRICK
FRCS, FRACS.

Our screening manager usually has our screening figures up to date. We saw slightly fewer patients with a higher referral rate and a lower percentage of life-threatening lesions. This may be due to Covid and a reclassification of life-threatening lesions. I will not elaborate further on our results.

About 12 screeners took part in the program this year which means that each screener screened on about 3 weekends. Unfortunately, this is a skewed picture as some screeners did a lot more and without them the program could not continue. Recruiting suitable staff is difficult as it is often a four-day weekend as travel may be taken on Friday and Monday between distant venues. When recruiting it is important to train people who have an ongoing commitment to our program as the course on Dermoscopy is only the beginning. Further practical experience is vital, and seminars or webinars consolidate their training. A big thank you to Kylie Laverty who is very well trained as a professional nurse and Dermoscopist who has organized a number of webinars. She suggests references for further reading in dermoscopy, prevention and self-examination. It remains disappointing that there only 5 medically trained screeners are regularly participating in the program, but this is a trend in volunteering

Despite the Minister of Health claiming there is no benefit from screening on mortality, early diagnosis must have contributed to the overall mortality drop in the last 10 years although the overall incidence is still climbing. It is important that the Institute services rural populations as the number of GPs appears to have become worse with many towns without a regular GP. The GP has a big and increasing workload of psychiatric and paediatric problems and often patients almost must make an appointment to be sick, let alone a skin screening! Our numbers speak for themselves with a referral rate of between 15% and 30% of which over 20% are life threatening. That indicates over 240 lives could be saved by our efforts!

Visits to our three scholarship holders' laboratories have been curtailed since Covid so we have no first-hand experience of their activities. The program continues and there should be feedback from them in the annual report.

The Dermosensor promised to us in April was sent back as it was faulty and as yet it has not been replaced. This tool has been found useful in diagnosing skin cancers but is yet to find popular usage. We look forward to trialling it in the future.

■ Robert Fitzpatrick FRCS, FRACS—Plastic Surgeon (Retired)



**Lions Clubs International
FOUNDATION**

LCIF By the Numbers

- Formed in 1968
- Over US\$1.2 billion awarded
- US\$35.4 million funded 1,254 projects last year

LCIF Causes



VISION

Reduce avoidable blindness and visual impairment; improve quality of life



YOUTH

Provide access to education, health services, social, and skills-building programs



DISASTER RELIEF

Deeply engage in disaster relief efforts, preparing for whenever and wherever disaster strikes



HUMANITARIAN EFFORTS

Support programs for at-risk, vulnerable populations disproportionately impacted by social and economic factors



DIABETES

Respond to the global epidemic through multi-faceted initiatives



CHILDHOOD CANCER

Strengthen medical and social services to increase global life expectancy



HUNGER

Expand resources and infrastructure to address food shortages worldwide



ENVIRONMENT

Protect environmental health globally, generating positive ecological and humanitarian impact

Dear Lions,

Congratulations on receiving a grant from Lions Clubs International Foundation (LCIF) for your service project.

Since 1968, LCIF has awarded more than 18,000 grants totaling US\$1.2 billion to help Lions like you improve health and well-being, strengthen communities, and protect the most vulnerable among us. Like those grants, yours was made possible by financial support from Lions, their clubs, and friends of LCIF. These donors and I thank you for being responsible stewards of LCIF funds and look forward to learning of your project outcomes.

As you know, LCIF – your foundation – recently completed *Campaign 100: LCIF Empowering Service*, raising US\$325 million and exceeding our US\$300 million goal. This amazing success, made possible by the generosity of Lions like you, will enable LCIF support grant worthy projects such as yours and empower Lions globally to continue to magnify service impact in vision, youth, disaster relief, humanitarian efforts, diabetes, childhood cancer, hunger, and the environment. Funds raised also ensure we can respond rapidly during extreme crises, like our global pandemic and the war in Ukraine. However, this historic campaign is just a milestone – not a destination – for our organization. As the calls to meet the needs of the world continue to grow, continued support of LCIF is imperative to ensure Lions can always answer. Learn more at lcif.org.

Whether your project takes place over a day, a week, a month, or years, thank you for reporting your progress along the way. Also, share related stories, pictures, and even brief videos with LCIF, on social media, and with your local newspaper. I'm confident the much-needed change you're creating will be a great source of comfort and hope for your community.

Once again, all the best as you embark on your project.

Yours in service,

Douglas X. Alexander

Douglas X. Alexander
Chairperson, Lions Clubs International Foundation

SCREENING EVENTS MANAGER REPORT



JOHN OSBORNE

This year began with the continuation of the screening program in the Kimberley and Pilbara. Centres covered were Derby, Kununurra, Lake Argyle, Wyndham, Broome, Marble Bar, Newman, Tom Price and Paraburdoo and returning home by the end of August. From September through to end of June we screened in the following locations Kellerberrin, Cunderdin, Williams, Darkan, Brookton, Beverley, Narrogin, Rockingham, Australind, Waroona, Northam, York, Nannup, Bridgetown, Manjimup, Kojonup, Brunswick, Collie, Augusta, Margaret River, Cowaramup, Vasse, Dunsborough, Busselton, Dallingin, Moora, Narembeen and Bruce Rock.

An online booking system was introduced in the last half of the year. Host organisations have the choice of using the manual or online booking for their event.

Screening events were hosted by Lions Clubs, Rotary Clubs, CWA, Men's Sheds, and CRC's. Our Thanks go to those organisations who willingly promote our screening clinics in their towns.

During the year we implemented practices to reduce the risk of Covid to our screening teams and clients. We had no reports of clients testing positive following attending a screening event. During the year we did not cancel any planned events due to Covid.

The Free Skin Screening program throughout Western Australia would not be possible without the generous help from our team of Volunteers. Their freely given time enables us to provide this much needed service to the rural and remote areas of our state. Thank you to the screeners, drivers and administrators.

NB: all figures below are for the 01/07/2021 - 30/06/2022 period.

SCREENING RESULTS 2021 - 2022

Number of Referrals	631
% Referred	20%
Life Threatening Lesions	275
Screened less than 6 months	134
Screened 6 - 12 months	390
Screened over 12 months	1763
Never Screened	851

3138 TOTAL SCREENED

SCREENING EVENTS

Number of Locations	41
Days Screening	51
Hours Screening	1630

15164 KM TRAVELLED

SCREENING UNITS

No major maintenance work was required on the Screening unit during the year.


Maintenance is now being done by Austransit (Mandurah Bus charters) at their Mandurah Depot.

■ John Osborne—Screening Events Manager




SCREENING EVENTS MANAGER REPORT

IDENTIFIED AS SUSPECT LESIONS 2021/2022




SCREENING AGE RANGE 2021/2022



SCREENING BY GENDER* 2021/2022

*Data shown as per our inclusive data collection policy.

35% Female
25% Male
0% Non-Binary
0% Other





▲ DRIVER PETER RUSSELL (CENTRE) WITH NAREMBEEN LIONS GREG RUTHERFORD AND RAY HENDERER



▲ THE SCREENING TEAM AT BUSSELTON



▲ DR. LESTER COWELL, PETER RUSSELL, PAULINE DILLEY, DAVID TURNELL AT ESPERANCE



▲ SCREENER PAULINE TRYING OUT THE DRIVER'S SEAT



▲ EVENTS MANAGER JOHN OSBORNE WITH HOST LIONS AT BOYUP BROOK



▲ COACH AT BRUCE ROCK



KAREN AND JOSHUA CHINNERY SCHOLARSHIP PHD STUDENT'S FIRST REPORT



SAMANTHA BARNES

PROJECT TITLE

Supercharging natural killer (NK) immune cells to eliminate leukaemia.

SUMMARY

Therapies that harness the patient's own immune system to fight cancer (known as immunotherapies) have shown remarkable success for patients with advanced leukaemia. However, these therapies are expensive, time-consuming, and not all patients are able to donate their own cells. This means there is an urgent need for an alternative approach. Our solution is to use the cancer killing immune cell, the natural killer (NK) cell, which can be collected from healthy donors, stored for later use, and given to multiple patients as soon as treatment is required. In this project we will develop new methods to enhance the activity of NK cells against leukaemia using immune-boosting molecules known as interferons [Aim 1]. We will also use cutting-edge genetic technologies to understand why some NK cells are better at killing leukaemia than others [Aim 2], and we will then use this information to "supercharge" NK cells to further enhance and refine their cancer killing abilities [Aim 3]. Our long-term goal is to create a highly effective NK cell therapy to ensure all patients can receive this life-saving treatment.

PROJECT UPDATE - SEPTEMBER 2022

Aim 1

We carried out a screen of all the different types of interferons to determine which subtype was the best at promoting NK cell activity against leukaemia in the lab. Once we identified our top three candidates, we then tested the ability of these interferons to improve the effectiveness of an NK cell therapy against leukaemia in a preclinical mouse model. Importantly, we observed that NK cells activated with a specific subtype (IFN α 14) were significantly more effective at treating leukaemia. This result was very exciting, and we believe that further

research into this interferon subtype holds promise for boosting the response rates of future NK cell therapies. We are currently in the process of writing a paper about this project which we hope to publish by the end of this year.

Aim 2.

In this aim we are using several cutting-edge sequencing technologies to determine which genes are switched "on" and "off" in different NK cells to identify the biological and molecular mechanisms that dictate their level of activity against leukaemia. We have performed several major sequencing experiments on NK cells with "high" and "low" abilities to eliminate leukaemia. So far, we have fully analysed one experiment which will be further investigated in Aim 3. We are currently analysing the remaining experiments, including one experiment that will allow us to tell which genes are on/off at a single-cell level, and hope to have more results soon.

Aim 3

Results from Aim 2 have allowed us to identify a biological pathway that we believe is a critical regulator of NK cell potential. We have been able to target this pathway in NK cells using several different drugs, which has allowed us to either boost or inhibit NK cell responses against leukaemia in the lab. We are currently investigating whether the addition of known NK cell activators can work alongside these drugs to further boost NK cell responses against leukaemia and other cancers. Additionally, we are currently investigating other strategies which will allow us to target this pathway more permanently.

We are very excited by the results from this project so far. We believe these findings will have a significant impact on the field of immunotherapy, and we hope these results will lead to the development of more effective NK cell therapies which will ultimately improve outcomes for patients with leukaemia.

■ Samantha Barnes PhD student Telethon Kids Institute

KAREN AND JOSHUA CHINNERY SCHOLARSHIP PHD STUDENT'S SECOND REPORT



HANNA NEWNES

Research Report: Cancer Council WA Research Program

Cancer Council WA Student PhD Top Up Scholarship (2021)

PROJECT TITLE

Harnessing the functional diversity of individual type I interferons to eliminate cancer.

PROJECT DESCRIPTION

Immunotherapies work by boosting the immune system to clear tumours. While there have been impressive results, unfortunately a number of patients fail to respond. This project aims to understand the immune response driving elimination versus cancer escape, which is classically a binary response. Patients either have a 'hot' immune active tumour which is responsive to therapies or a 'cold' immune inactive tumour which is unresponsive to therapy.

Our early data suggests for successful treatment patients require a balance of both 'hot' and 'cold' signals to drive a finely tuned 'warm' environment. An 'overheated' response drives a short but ultimately ineffectual immune response, which may explain why some patients with a 'hot' tumour fail to respond to therapy. Using current technology, we can investigate the mechanisms driving 'warm' responses to recapitulate them in the laboratory. Using this knowledge, we can stratify patients and deliver personalised therapies to switch them from 'overheated' or 'cold' tumours to 'warm' tumours to improve their response to current therapies.

PROJECT UPDATE:

Immunotherapies work by boosting the immune system to clear tumours. While there have been impressive results, unfortunately many patients fail

to respond. Ms Newnes's work has aimed to understand the immune response which drives the elimination of cancer as opposed to the immune response which allows the cancer to grow unchecked.

So far, the findings from this research have advanced her knowledge of cancer progression by identifying Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight cancer. Whilst remarkable clinical results have been observed in patients with blood cancers there are several challenges limiting its success in solid cancers (e.g., melanoma and sarcoma). ACT can fail because

- i) transferred T cells do not survive long in the patient.
- ii) the patient's immune system and cancer inhibit the function of the transferred T cells.
- iii) transferred T cells are unable to infiltrate into the cancer.

One way to overcome these problems is by engineering the T cells in the lab to give them additional weapons before they are transferred into patients. Using our findings from previous work we have identified a list of genes to turn 'on' and 'off' that can help or hinder T cells, respectively. Using this information as a blueprint for successful T cells, we can turn 'on' or 'off' these genes in our T cells that we use for ACT, to develop better ACT products and improve response rates.

This past year, Ms Newnes optimised a genetic engineering platform to successfully turn 'on' or 'off' a selection of her candidate genes. In addition to this she has shown delayed tumour growth when targeting one of her top candidate genes. She continues to work on this project targeting additional genes to create the most effective T cell therapy and further improve tumour outcomes.



CHIRI PHD STUDENT'S FIRST REPORT

During this project she has identified multiple differences in the immune cells found within tumours which are either cleared by the immune system or allowed to grow unchecked. These are often called 'hot' or 'cold' tumours respectively. Ms Newnes has described a 3rd category of tumours she has called 'overheated'. These tumours have an overactive immune response which drives a short and ineffective response and therefore the cancer continues to grow. In this past year, she found that the T cells in 'overheated' tumours are dysfunctional. T cells, also known as killer T cells, are a critical immune cell that can kill cancerous cells preventing the continued growth of the cancer. The dysfunction in this cell compartment is likely to be a major contributor to the ineffective immune response observed in 'overheated' tumours. Ms Newnes has also identified a lack of another cell population, called dendritic cells, in 'overheated' tumours. Like generals in an army, these dendritic cells are critical in organising the immune response and activating the killer T cells. Therefore, a lack of these 'generals' or dendritic cells may ultimately be why the immune response is unable to properly fight the cancer. She has used this knowledge to identify drugs or genes we can target to switch on these cells and arm the T cells to fight the cancer cells and stop their growth.

Ms Newnes also made the following comments: "I am extremely grateful to the Cancer Council Western Australia and the Lions Cancer Institute in supporting my research. Particularly in these last couple of years which have been quite different to expected with the global pandemic and have limited many of the opportunities to share my research on a broader scale. I am greatly looking forward to the opportunity to continue my work and share my findings with the academic community by attending scientific conferences and having the opportunity to do more outreach and community engagement."

■ Hannah Newnes PhD student Telethon Kids Institute



ANJALI GHIMIRE

PROJECT TITLE

Predicting liver cancer prior to its development to improve early detection and survival.

PROJECT COMMENCED

March 2022

EXPECTED COMPLETION

September 2025

Hepatocellular carcinoma (HCC), the most common type of liver cancer, causes about 10% of all cancer-related deaths globally. In Australia, HCC is the fastest increasing cause of cancer death. HCC develops secondary to underlying chronic liver diseases such as viral hepatitis, alcoholic liver disease and, increasingly, non-alcoholic fatty liver disease (NAFLD). Currently, there are no reliable methods available to predict which patients have an increased risk of future HCC development. The consequence is the lack of surveillance programs for early detection of HCC, which results in late diagnosis and poor survival of patients. Hence, my research aims to develop a new approach to detect early signs of future liver cancer development before the disease can be diagnosed by current methods.

Cancers develop progressively as a series of changes occur stepwise converting a healthy cell into a malignant one. Our team has recently characterised in depth the molecular fingerprint of pre-malignant liver cells. My study will develop methods to detect and quantify the presence of these pre-malignant cells in liver disease patients. We believe they can be detected well in advance in high-risk patients, and before liver cancer develops. Early detection will be a game changer for liver cancer patients and is expected to improve survival and quality of life. If successful, this project will enable the establishment of evidence-based surveillance programs for early detection of HCC.

■ Anjali Ghimire PhD student Curtin University

CHIRI PHD STUDENT'S SECOND REPORT



NATHAN MAIN

PROJECT TITLE

Investigating TWEAK/Fn14 signalling during chronic liver disease.

Project commenced:

August 2020

Expected Completion:

Mid 2023 - End of 2023

PROJECT SUMMARY

Researchers over the past 2 decades have been interested in developing therapeutics to target a small protein called Fn14, with the aim of preventing its activation. Several generations of therapeutics (called anti-TWEAKs) have been developed to prevent Fn14 activation, but all have proven unsuccessful. These therapeutics were originally developed to treat a range of inflammatory-related disorders, including rheumatoid arthritis and chronic liver disease, as well as cancers such as melanoma, glioma and liver cancer. However, these therapeutics proved ineffective, and their use has been discontinued. My PhD project involves characterising a novel mechanism of Fn14 activation that allows Fn14 to become resistant to anti-TWEAK therapeutics.

Overall, we hope that uncovering this novel and alternative mechanism of Fn14 activation will lead to new therapeutic strategies to target Fn14 during chronic liver disease and liver cancer. Since the anti-TWEAK therapeutic was developed to treat a range of inflammatory diseases and cancers, we believe this discovery will also have significant implications for a variety of other diseases and not just chronic liver disease.

RESEARCH PROGRESS

I am expanding my initial discovery of the alternative

activation mechanism and characterising this process with a focus on identifying methods to prevent Fn14's activation. I am on track to thoroughly characterising this process by the end of my PhD. I am hoping that, when this work is completed, we will be able to develop a strategy to prevent Fn14's activation by the alternative mechanism. This will open avenues for novel therapeutic strategies that leverage the new findings I am uncovering.

■ Nathan Main PhD student Curtin University




COMMUNITY EVENTS

STUDENTS HANNAH ▶
& SAMANTHA WITH
CHAIRMAN PHIL



VOLUNTEER
◀ SCREENERS KYLIE
LAVERTY & PAULINE
DILLEY
PRESIDENT,
WYALKATCHEM
ROTARY CLUB, JAN
TRENORDEN
ADMINISTRATION
TRISH CHINNERY
& CHAIRMAN PHIL
CHINNERY

FORMER LCI ▶
CHAIRMAN AND
SENIOR SCREENER
PDG COLIN
BEAUCHAMP AM,
SCREENING
AMBASSADOR
DEBORAH HUTTON.



TREASURER'S REPORT



LION ROBERT GARRATT

It has been an interesting year with fund raising. Our Telemarketing group has done an excellent job, and this resulted in us moving to Teir3 for auditing purposes. Our accountant found us a Registered Company Auditor which is the requirement for Tier 3 Audits. They were given a short time frame to get the audit done and with many questions, so he understood our operation, he gave us a clear report with some notes for the board to analyse.

There has been a change in the level for reporting and we will next year be back to a Tier 2 which our accountant is able to do at a reduced cost.

OPERATIONAL ACCOUNTS

Xero is working well and we are now giving prompt receipts that are readily emailed to all needing one. I can get many reports for answers to questions asked by the board.

There is a lag between Show Account (Telemarketing) income due to it being credited to our account the following month. We have had several incorrect transactions within the Telemarketing bank (one where a company paid us \$30,000 which should have been a payment to one of their other business, so we refunded this to the company), other small errors are recorded as Telem Errors, this is required so reconciliation can be done correctly.

Our screening expenses increased due to activities in the North of the State but are still within the budget estimated costs.

We have been doing changes to the Web site to start to get it updated.

The development of the QR (Quick Response) for donations took some time due to setting up of the financial framework. We will be using this facility to identify the source for a lot of donations in the future.

I have put in future income from round 2 Pledges (still Outstanding) that show up as Trade receivables and future expenses of Scholarship commitments as I know of for the next few years, and these are in the Trade and Other Payables

Clubs have responded well to their pledges and have helped to get towards our target for the new vehicle. The generosity of our clubs is what keeps us being able to provide the services and student sponsorship happening.

During this year we received pledges from many clubs to the value of \$94,000. Along with Corporate donations we raised a total of \$277,929 towards the replacement vehicle (\$117,000 from Telemarketing). Many of the Board members have been very active in chasing up grants and donations, these have put us in a great place to start planning the new vehicle in our next financial year. As at 26th Sept 2022 we have raised a Total of \$537,525 (Includes a grant from LCIF) towards a total of \$650,000 for the vehicle.

PORTFOLIO

We have had a major change in our portfolio. We closed the First Choice Account at end of June 2022 and withdrawn the funds to be held in our Cheque account pending the funds to be transferred (Mid July 2022) into a new Stirling Managed Investments as advised by our advisors Acumen Wealth. The financial market over the year has been negative and this has resulted in a loss over the year

Opening Balance 30.07.2021 - \$107593.18, We withdrew \$220500 to support the Funds required for the replacement vehicle and a final withdrawal of \$819216.19 at the end of the year. The closing balance in the First Choice investment account was Zero as at 30.06.2022 . A loss of \$36200 The financial Income Statement shows this as "Portfolio Distribution income" less "Decrease in Market Investments"

We pay for advice from advisors and trust that it is good for the Institute going forward to enable us to continue to provide the services to education and the community.

A big thanks to our accountant Dharam and PDG Neil, who have been so helpful in organising the changes in Xero, to David Baird who has been invaluable in mastering the reconciliation of the Telemarketing Account, this has many transactions every day.

■ Lion Robert Garratt – Treasurer

DIRECTOR'S REPORT

Your directors present their report on the Institute for the financial year ended 30 June 2022. The names of the Directors in office at the date of this report are:

ELECTED MEMBERS

Lion Phil Chinnery	Chairman
PDG Michael Wainwright	Vice Chairman
PDG Pamela Baird	Director
PDG Garry Irvine	Director Business Development
Lion Pip Dargaville	Director
Lion John Osborne	Director Screening Event Coordinator
Lion Hans Hoette	Director
Lion Christine Walker	Director
Lion Graham Bateman	Director
Lion David Turnell	Director

EX OFFICIO MEMBERS

DG. Michael Wolf	DG District 201W1
DG. Stephen Berry	DG District 201W2
1 st VDG Darren Blackburn	VDG District 201W1
1 st VDG Ted Watts	VDG District 201W2
2 nd VDG Tim Moore	District Chairman 201W1

APPOINTED MEMBERS

Mr. William Crosthwaite	Secretary
Lion Robert Garratt	Treasurer
Dr Rob Fitzpatrick, FRCS, FRACS	Chair Medical & Scientific Advisory Committee

CHANGE IN DIRECTORS DURING THE 2021/2022 FINANCIAL YEAR

DG Michael Wainwright	End of term
DG Dot Jacobs	End of term
Lion Pip Dargaville	Elected
Lion Hans Hoette	Elected
Lion Christine Walker	Elected
Lion Graham Bateman	Elected
Lion David Turnell	Elected

CO-OPTED, NON-VOTING, MEMBERS

PDG Neil F. Saunders	Financial Advisor
Lion David Baird	Assist. Treasurer

No significant changes in the Institute's state of affairs occurred during the financial year.

The Lions Cancer Institute Inc. is a "Not for Profit" medical research institution. The Institute holds endorsements for the Australian Taxation Office as an Income Tax exempt Charitable Entity (ITEC) and is a Deductible Gift Recipient (DGR). The Institute is also registered with Australian Charities and Not for Profits Commission (ACNC).

The Institute holds a current West Australian Charitable Collections Licence under the provisions of the Charitable Collections Act 1946.


No significant change in the nature of these activities occurred during the year.

Any significant increase to "Cash in Bank" figures is mainly due to the ongoing fundraising for the purchase of a replacement screening vehicle.

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Institute, the results of those operations, or the state of affairs of the economic entity in future financial years.

Signed in accordance with a resolution of the Board of Directors:

Philip Chinnery
Chairman
Place: Mandurah Dated: 08.09.2022



Lion Robert Garratt
Treasurer
Place: Mandurah Dated: 08.09.2022



FINANCIAL REPORT

INCOME AND EXPENDITURE STATEMENT FOR THE YEAR ENDED 30 JUNE 2022

	NOTES	2022	2021
Income			
Grant Operating		1,000	-
Donations	2	231,453	151,778
Fundraising		3,093	-
Show account income		1,326,942	1,201,927
Portfolio distribution income		42,555	39,092
Other income	3	1,488	47,727
Increase/(decrease) in market value of investments		(73,742)	60,808
Total Income		1,532,789	1,501,333
Gross Surplus		1,532,789	1,501,333
Expenditure			
Accounting and audit		5,861	6,594
Advertisement costs		-	4,049
Advisor fees		2,344	2,534
Bank charges		29	655
Computer and software costs		678	1,168
Depreciation		6,537	39,259
Fundraising expenses		1,220,874	809,614
Generator expenses		781	4,620
Rental expenses		4,399	5,945
Other employer expenses		4,463	3,781
Printing, postage and stationery		1,022	1,711
Presentations		-	2,556
Public relations expenses		5,828	4,051
Scholarship and award expenses		55,000	42,000
Screening expenses		71,956	59,472
South Australia setup		-	800
Sundry expenses		2,233	8,003
Sustenance Costs (Screening)		-	7,306
Telem Error		12,599	-
Telephone expenses		1,531	1,986
Vehicle maintenance		20,952	38,029
Transportation expenses		-	5,142
Web site expenses		3,178	1,523
Total Expenditure		1,420,264	1,050,799
Current Year Surplus/ (Deficit) Before Income Tax Adjustments		112,524	450,533
Current Year Surplus/(Deficit) Before Income Tax		112,524	450,533

ASSETS AND LIABILITIES STATEMENT AS AT 30 JUNE 2022

	NOTES	30 JUN 2022	30 JUN 2021
Assets			
Current Assets			
Cash and cash equivalents		1,738,901	429,478
Trade and other receivables	4	26,900	3,500
GST receivable		2,214	6,829
Other current assets	5	5,432	389
Total Current Assets		1,773,447	440,197
Non-Current Assets			
Financial assets	6	-	1,075,939
Plant, equipment and vehicles	7	27,734	33,017
Intangibles		-	1,954
Total Non-Current Assets		27,734	1,110,910
Total Assets		1,801,181	1,551,106
Liabilities			
Current Liabilities			
Credit card liabilities		537	2,809
Trade and other payables	8	139,955	133
Total Current Liabilities		140,493	2,942
Total Liabilities		140,493	2,942
Net Assets		1,660,689	1,548,164
Equity			
Accumulated surplus		1,660,689	1,548,164
Total Equity		1,660,689	1,548,164

MOVEMENTS IN EQUITY

	2022	2021
Equity		
Opening Balance	1,548,164	1,097,631
Increases		
Surplus for the period	112,524	450,533
Total Increases	112,524	450,533
Total Equity	1,660,689	1,548,164

FINANCIAL REPORT

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2022

	2022	2021
Operating Activities		
Receipts from customers	1,539,288	1,356,253
Payments to suppliers and employees	(1,265,676)	(1,192,416)
Portfolio distribution received	34,779	36,436
Interest received	89	275
Net Cash Flows from Operating Activities: Note 9	308,480	200,549
Investing Activities		
Proceeds from sale of property, plant and equipment	-	40,000
Proceeds from sale of investments	1,002,197	(83,898)
Payment for property, plant and equipment	(1,255)	(29,587)
Net Cash Flows from Investing Activities	1,000,942	(73,485)
Financing Activities		
Other cash items from financing activities	-	-
Net Cash Flows from Financing Activities	-	-
Net Cash Flows	1,309,422	127,063
Cash and Cash Equivalents		
Cash and cash equivalents at beginning of period	429,478	302,415
Net increase/(decrease) in cash for period	1,309,422	127,063
Cash and cash equivalents at end of period	1,738,901	429,478



DIRECTOR'S DECLARATION FOR THE YEAR ENDED 30 JUNE 2022

The Board of Directors have determined that the Association is not a reporting entity and that this special purpose financial report should be prepared in accordance with the accounting policies outlined in Note 1 to the financial statements, the attached special purpose financial statements have been prepared for the purpose of complying with the Association Incorporation Act 2015 (WA), the Australian Charities and Not-for-Profits Commission Act 2012 and association regulations.

The directors of the Association declare that:

1. The financial statements and notes attached give a true and fair view of the financial position as at 30/06/2022 and its performance for the year ended on that date in accordance with the accounting policies described in Note 1 to the financial statements.
2. In the director's opinion there are reasonable grounds to believe that the incorporated association will be able to pay its debts as and when they become due and payable.

This statement is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the directors by:

Phil Chinnery	
Chairman	
Dated:	15/09/2022
Lion Robert Garratt	
Treasurer	
Dated:	15/9/22.

Notes to the Financial Statements

LIONS CANCER INSTITUTE (WA) INC

For the year ended 30 June 2022

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

(a) **Basis of Preparation**

This financial report is a special purpose financial report prepared in order to satisfy the requirements of Board members to prepare a financial report. The Board members have determined that the Association is not a reporting entity. The financial report has been prepared in accordance with the requirements of Association Incorporation Act 2015 (WA), association regulations.

The financial statements have been prepared on an accruals basis and are based on historic costs and do not take into account changing money values or, except where specifically stated, current valuations of non-current assets.

The following material accounting policies, which are consistent with the previous period unless otherwise stated, have been adopted in the preparation of the financial statements.

(b) **Cash and Cash Equivalents**

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short term highly liquid investments with original maturities of three months or less.

(c) **Property, Plant and Equipment**

Leasehold improvements and office equipment are carried at cost less, where applicable, any accumulated depreciation.

The depreciable amount of all PPE is depreciated over the useful lives of the assets to the association commencing from the time the asset is held ready for use.

Leasehold improvements are amortised over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

(d) **Impairment of Assets**

At the end of each reporting period, the Board reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs of disposal and value in use, to the asset's carrying amount. Any excess of the asset's carrying amount over its recoverable amount is recognised in the income and expenditure statement.

(e) **Accounts Receivable and Other Debtors**

Accounts receivable and other debtors include amounts due from members as well as amounts receivable from donors. Receivables expected to be collected within 12 months of the end of the reporting period are classified as current assets. All other receivables are classified as non-current assets.

(f) **Revenue and Other Income**

Revenue is recognised when the amount of the revenue can be measured reliably, it is probable that economic benefits associated with the transaction will flow to the entity and specific criteria relating to the type of revenue as noted below, has been satisfied.

Revenue is measured at the fair value of the consideration received or receivable and is presented net of returns, discounts and rebates. For this purpose, deferred consideration is not discounted to present values when recognising revenue.

Interest revenue is recognised using the effective interest method, which for floating rate financial assets is the rate inherent in the instrument. Dividend revenue is recognised when the right to receive a dividend has been established.

Grant and donation income is recognised when the entity obtains control over the funds, which is generally at the time of receipt.

If conditions are attached to the grant that must be satisfied before the association is eligible to receive the contribution, recognition of the grant as revenue will be deferred until those conditions are satisfied.

Other revenue is recognised when the institute is entitled to the funds.

All revenue is stated net of the amount of goods and services tax.

(g) Leases

Leases of PPE, where substantially all the risks and benefits incidental to the ownership of the asset (but not the legal ownership) are transferred to the association, are classified as finance leases.

Finance leases are capitalised by recording an asset and a liability at the lower of the amounts equal to the fair value of the leased property or the present value of the minimum lease payments, including any guaranteed residual values. Lease payments are allocated between the reduction of the lease liability and the lease interest expense for that period.

Leased assets are depreciated on a straight-line basis over the shorter of their estimated useful lives or the lease term. Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are charged as expenses in the periods in which they are incurred.

(h) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.

(i) Financial Assets

Investments in financial assets are initially recognised at cost, which includes transaction costs, and are subsequently measured at fair value, which is equivalent to their market bid price at the end of the reporting period. Movements in fair value are recognised through an equity reserve.

(j) Accounts Payable and Other Payables

Accounts payable and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the association during the reporting period that remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

(k) Provisions

Provisions are recognised when the association has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions are measured at the best estimate of the amounts required to settle the obligation at the end of the reporting period.

(l) Income Tax

Lions Cancer Institute Inc. is exempt from income tax and registered as deductible gift recipient.

	2022	2021
2. Donations		
Donations Screening Unit	-	13,163
Donations Private	-	12,326
Donations Corporate	-	3,625
Donations, All Other Sources	103,148	21,311
Vehicle Replacement	128,305	101,353
Total Donations	231,453	151,778

	2022	2021
3. Other Income		
Fuel Tax Credits	1,244	726
Insurance Refunds	-	1,555
Interest Bank A/c	89	72
Interest Investment	-	202
Miscellaneous Income	155	4,372
SA Telemarketing	-	800
Sale of Assets	-	40,000
Total Other Income	1,488	47,727

	2022	2021
4. Trade and Other Receivables		
Trade debtors	26,900	3,500
Total Trade and Other Receivables	26,900	3,500

	2022	2021
5. Other Current Assets		
Fuel Tax Receivable	-	271
Credit Card Rob Garratt	(215)	118
Total Other Current Assets	(215)	389

	2022	2021
6. Financial Assets		
FirstChoice Wholesale Investments	-	1,075,939
Total Financial Assets	-	1,075,939

2022 2021

7. Plant and Equipment, Motor Vehicles

Plant and Equipment		
Plant and Equipment at Cost	31,547	30,293
Accumulated Depreciation of Plant and Equipment	(30,447)	(29,890)
Total Plant and Equipment	1,101	403
Motor Vehicles		
Motor Vehicles at Cost	335,341	335,341
Accumulated Depreciation of Motor Vehicles	(308,708)	(302,728)
Total Motor Vehicles	26,633	32,613
Total Plant and Equipment, Motor Vehicles	27,734	33,017
	2022	2021

8. Trade and Other Payables

Trade Payables	138,513	133
Total Trade and Other Payables	138,513	133

9. Cash Flow Information

For the purpose of the statement of cash flows, cash includes cash on hand and in at call deposits with banks or financial institutions, investments in money market instruments maturing within less than two months net of bank overdrafts.

a. Reconciliation of Cash

Cash at the end of the reporting period as shown in the statement of cash flows is reconciled to the related items in statement of financial positions as follows :

b. Reconciliation of Cash Flow From Operations with Net income

	2022	2021
Net current year surplus income after income tax	112,524	450,533
Depreciation and amortisation	8,491	43,211
Increase/(Decrease) in market value of investments	73,742	(60,808)
(Increase)/Decrease in Trade and other receivables	(23,828)	(9,113)
Increase/(Decrease) in Trade and other payables	137,551	(183,274)
(Gain)/Loss sale of assets	-	(40,000)
Cash flow from operations	308,480	200,549



INDEPENDENT AUDIT REPORT FOR THE YEAR ENDED 30 JUNE 2022

Independent Audit Report to the members of Lions Cancer Institute (Inc)

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Lions Cancer Institute Inc, which comprises the statement of financial position as at 30 June 2022, the statement of profit or loss, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the statement by the members of the board.

In our opinion the financial report of Lions Cancer Institute Inc has been prepared in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) giving a true and fair view of the Registered Entity's financial position as at 30 June 2022 and of its financial performance for the year ended; and
- (ii) complying with Australian Accounting Standards to the extent described in Note 1, and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Registered Entity in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter - Basis of Accounting

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the Registered Entity's financial reporting responsibilities under the ACNC Act. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Responsibilities of Responsible Entities for the Financial Report

The responsible persons of the Registered Entity are responsible for the preparation of the financial report that gives a true and fair view and have determined that the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act and the needs of the members. The responsible entities' responsibility also includes such internal control as the responsible entities determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the responsible persons are responsible for assessing the Registered Entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the responsible entities either intend to liquidate the Registered Entity or to cease operations, or have no realistic alternative but to do so.

INDEPENDENT AUDIT REPORT FOR THE YEAR ENDED 30 JUNE 2022 (ctd)

Independent Audit Report to the members of Lions Cancer Institute (Inc)

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Registered Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the responsible entities.
- Conclude on the appropriateness of the responsible entities' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Registered Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Registered Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



Daniel Papaphotis
Registered Company Auditor
- 410503
Francis A Jones Pty Ltd
Fremantle WA 6160

Dated: 20th September 2022



What Patients Should Know About Skin Cancer

Preventing skin cancer is also about knowing your risk level. The most effective management is early detection and treatment.

1. UNDERSTANDING WHAT SUN DAMAGE & SKIN CANCER IS / HOW IT LOOKS
2. INDIVIDUAL RISK
3. HOW TO SELF CHECK
4. FIVE PREVENTION MEASURES

ARE YOU AT A HIGHER RISK FOR SKIN CANCER? Find a top doc

Your risk for contracting skin cancer is greater if you have:

- Fair skin color
- Fair hair color
- Fair eye color
- Freckles
- Moles

OR

If you're over 65, or have a family or personal history of skin cancer.

Treat your skin right to prevent skin cancer!
Follow these simple tips to protect your skin:

- Wear sunscreen year round
- Wear protective clothing
- Avoid tanning beds
- Avoid the sun in the middle of the day
- Be aware of sun-sensitive medications
- Check your skin regularly
- Meet regularly with a dermatologist

LIONS CLUB DONATIONS 2021-2022

CLUB	CLUB	CLUB
Albany South Coast	Duncraig Inc.	Millbridge
Armadale-Kelmscott LC	Dunsborough	Moora
Atwell	East Fremantle	Mount Barker
Australind	Ellenbrook	Nannup
Baldivis	Falcon	Narembeen
Bassendean	Geraldton	Narrogin
Boddington	Gingin-Chittering	Noranda
Booragoon	Girrawheen	North Beach
Boyanup	Gosnells Inc	Northam
Boyup Brook	Hannans Goldfields	Northampton
Bridgetown	Harvey	Pingrup
Broome	Hyden	Pinjarra
Brunswick Junction	Jandakot Lakes	Port Kennedy
Bull Creek	Katanning	Rockingham
Busselton	Kojonup	South Perth
Canning City	Kondinin	Stirling Inc.
Capel	Kulin	Tambellup
Carnarvon	Kwinana	Vasse
Claremont - Nedlands	Lake Grace	Wagin
Collie	Leeming	Wandering Inc.
Cowaramup	Leeuwin	West Arthur
Dardanup	Mandurah	Whitford
Dongara/Denison	Manjimup	
Donnybrook	Margaret River	

Total Donated by Lions Clubs
\$122,779.00



LIFE FELLOWS OF THE LIONS CANCER INSTITUTE INC.

PDG Garry Irvine	DIRECTOR, DERMOSCOPIST
Mr Robert Fitzpatrick MBBS FRCS FRACS (Retired)	DIRECTOR, PLASTIC SURGEON
Mr Barrie Lykke MBBS FRACS FRACS (Retired)	PLASTIC SURGEON
Professor Kurt Gebauer MBBS FACD	PROFESSOR OF DERMATOLOGY
Dr Lester Cowell MBBS	PRIMARY CARE SKIN CANCER PRACTITIONER
Mrs Monika Cowell	DERMOSCOPIST
Lion Susan Goddard BA APP. Sc. FRCNA (Retired)	REGISTERED NURSE
PDG Colin Beauchamp AM.JP	DERMOSCOPIST
PDG RON VAUGHAN (Deceased)	
Mr DON PHILLIPS (Deceased)	
Mr Alister Turner MBBS FRCS FRACS (Deceased)	PLASTIC SURGEON



30 years of Australian research and development ensures that SunSense sunscreens are for real Australian conditions and real Australian lifestyles. Developed to suit individual needs, SunSense sunscreens not only provide SPF protection, but offer the added benefits of moisturising Vitamin B3. The SunSense range is specifically formulated using high quality ingredients to provide specialised choices for all ages and skin types including sensitive skin and the delicate skin of young children.

All SunSense sunscreens are Australian made in Braeside, Victoria and Australian family owned.

Visit www.sunsense.com.au for more information.



Kwik Kopy Canning Vale has been established in the heart of Canning Vale since 1998. Fitz Cass has owned the company since 2007 and he is driven by a passion for the business and it's customers. Our success is due to constantly evolving together with our customers.

At Kwik Kopy Canning Vale, we keep things as simple as possible. We deliver great customer service from experienced staff and in-house production for fast, reliable service and high quality products. We can print just about everything you need.

Our goal is to offer you a wide range of products, from branding to print, signage, promotional products, merchandise, marketing, creative and digital services.

SAVING
lives **IN YOUR**
COMMUNITY THROUGH
screening **AND**
RESEARCH.



Lions Cancer Institute (WA) Inc.

PO Box 2195,
MANDURAH DC, WA 6210

Chairman

Mobile: 0428 420 275
Email: chairman@lionscancerinstitute.org.au

Treasurer

Mobile: 0450 288 221
Email: treasurer@lionscancerinstitute.org.au

www.lionscancerinstitute.org.au

 Find us on
Facebook